183 related articles for article (PubMed ID: 33563150)
41. Small Molecules Targeting Viral RNA.
Mathez G; Cagno V
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686306
[TBL] [Abstract][Full Text] [Related]
42. A strategy for evaluating potential antiviral resistance to small molecule drugs and application to SARS-CoV-2.
Sargsyan K; Mazmanian K; Lim C
Sci Rep; 2023 Jan; 13(1):502. PubMed ID: 36627366
[TBL] [Abstract][Full Text] [Related]
43. Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2.
Shannon A; Canard B
Antiviral Res; 2023 Feb; 210():105501. PubMed ID: 36567022
[TBL] [Abstract][Full Text] [Related]
44. Antiviral therapeutics directed against RNA dependent RNA polymerases from positive-sense viruses.
Bhatia S; Narayanan N; Nagpal S; Nair DT
Mol Aspects Med; 2021 Oct; 81():101005. PubMed ID: 34311994
[TBL] [Abstract][Full Text] [Related]
45. Initiation of Antiviral Treatment in SARS-CoV2: Modeling Viral Dynamics and Drug Properties.
Rosenbloom DS; Zhao P; Sinha V
CPT Pharmacometrics Syst Pharmacol; 2020 Sep; 9(9):481-483. PubMed ID: 32700405
[No Abstract] [Full Text] [Related]
46. Sars-Cov-2 and risk of antiviral drug resistance.
Vitiello A
Ir J Med Sci; 2022 Oct; 191(5):2367-2368. PubMed ID: 34714491
[No Abstract] [Full Text] [Related]
47. Characterizing single-molecule dynamics of viral RNA-dependent RNA polymerases with multiplexed magnetic tweezers.
Kuijpers L; van Laar T; Janissen R; Dekker NH
STAR Protoc; 2022 Sep; 3(3):101606. PubMed ID: 35959497
[TBL] [Abstract][Full Text] [Related]
48. Chemical Synthesis of the Antiviral Nucleotide Analogue ddhCTP.
Wood JM; Evans GB; Grove TL; Almo SC; Cameron SA; Furneaux RH; Harris LD
J Org Chem; 2021 Jul; 86(13):8843-8850. PubMed ID: 34126010
[TBL] [Abstract][Full Text] [Related]
49. COVID-19 and the Functionality of Antivirals: The Day After Tomorrow.
Sharifan A
Health Secur; 2022; 20(3):270-271. PubMed ID: 35723880
[No Abstract] [Full Text] [Related]
50. Progression of Antiviral Agents Targeting Viral Polymerases.
Peng S; Wang H; Wang Z; Wang Q
Molecules; 2022 Oct; 27(21):. PubMed ID: 36364196
[TBL] [Abstract][Full Text] [Related]
51. Is photodynamic therapy a viable antiviral weapon against COVID-19 in dentistry?
Joseph B; Prasanth CS
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Jul; 132(1):118-119. PubMed ID: 33627293
[No Abstract] [Full Text] [Related]
52. On coming back, the scaring COVID-19 concern. Addressing indoor microclimates with innovative and straightforward solutions to prevent SARS-CoV2 spreading.
Chirumbolo S; Tirelli U
J Med Virol; 2024 Feb; 96(2):e29490. PubMed ID: 38377130
[No Abstract] [Full Text] [Related]
53. Embracing Uncertainties Over the Evidence of New Oral Antivirals for COVID-19: Challenges in Pharmacoepidemiologic Research.
Ferreira da Silva R; Silva AM; Morato M; Ribeiro-Vaz I; Polónia JJ
J Clin Pharmacol; 2023 May; 63(5):521-525. PubMed ID: 36519976
[No Abstract] [Full Text] [Related]
54. New Antivirals and Immune Therapies for COVID-19 Infection.
Miro JM; Torres A; Paredes R
Arch Bronconeumol; 2022 Apr; 58 Suppl 1():8-10. PubMed ID: 35501220
[No Abstract] [Full Text] [Related]
55. Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors.
Ma C; Wang J
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33568498
[No Abstract] [Full Text] [Related]
56. [Intenational breakthroughs in critical care medicine 2020].
Liu C; Dai X; Huang W
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Jan; 33(1):5-9. PubMed ID: 33565392
[TBL] [Abstract][Full Text] [Related]
57. Artificially expanded genetic information systems (AEGISs) as potent inhibitors of the RNA-dependent RNA polymerase of the SARS-CoV-2.
Jena NR; Pant S; Srivastava HK
J Biomol Struct Dyn; 2022 Sep; 40(14):6381-6397. PubMed ID: 33565387
[TBL] [Abstract][Full Text] [Related]
58. Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.
Gyselinck I; Liesenborghs L; Landeloos E; Belmans A; Verbeke G; Verhamme P; Vos R; Janssens W;
Trials; 2021 Feb; 22(1):126. PubMed ID: 33563325
[TBL] [Abstract][Full Text] [Related]
59. An extended fuzzy decision-making framework using hesitant fuzzy sets for the drug selection to treat the mild symptoms of Coronavirus Disease 2019 (COVID-19).
Mishra AR; Rani P; Krishankumar R; Ravichandran KS; Kar S
Appl Soft Comput; 2021 May; 103():107155. PubMed ID: 33568967
[TBL] [Abstract][Full Text] [Related]
60. DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19.
Bejan CA; Cahill KN; Staso PJ; Choi L; Peterson JF; Phillips EJ
medRxiv; 2021 Feb; ():. PubMed ID: 33564788
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
